388 related articles for article (PubMed ID: 17659849)
1. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
5. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
Tuveson DA; Willis NA; Jacks T; Griffin JD; Singer S; Fletcher CD; Fletcher JA; Demetri GD
Oncogene; 2001 Aug; 20(36):5054-8. PubMed ID: 11526490
[TBL] [Abstract][Full Text] [Related]
6. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
8. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
9. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
10. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
11. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
Duensing A; Medeiros F; McConarty B; Joseph NE; Panigrahy D; Singer S; Fletcher CD; Demetri GD; Fletcher JA
Oncogene; 2004 May; 23(22):3999-4006. PubMed ID: 15007386
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic and predictive role of kit (CD117)].
Dirnhofer S; Zimpfer A; Went P
Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
[TBL] [Abstract][Full Text] [Related]
14. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
Paner GP; Silberman S; Hartman G; Micetich KC; Aranha GV; Alkan S
Anticancer Res; 2003; 23(3B):2253-60. PubMed ID: 12894500
[TBL] [Abstract][Full Text] [Related]
15. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
16. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal stromal tumors (GIST)].
Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
[TBL] [Abstract][Full Text] [Related]
18. [Gastrointestinal stromal tumor].
Nishida T; Ohmori T; Matsuda H
Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
Hirota S; Nishida T; Isozaki K; Taniguchi M; Nakamura J; Okazaki T; Kitamura Y
J Pathol; 2001 Apr; 193(4):505-10. PubMed ID: 11276010
[TBL] [Abstract][Full Text] [Related]
20. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]